Search clinical trials for: PEG Interferon Alfa-2b

Total 1096 results

Brooke Army Medical Center
T.R.U.E. Research Foundation

Completed

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Hepatitis C

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Recurrence | Hematological Neoplasms

China
Merck Sharp & Dohme LLC

Terminated

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

P1101 in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

Lymphoma

United States
M.D. Anderson Cancer Center
Schering-Plough

Terminated

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Leukemia, Myeloid, Philadelphia-Positive

United States
St. Jude Children's Research Hospital
Schering-Plough

Active, not recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Malignant Melanoma

United States
University of Miami

Recruiting

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Adult T-cell Leukemia-Lymphoma | ATLL

United States
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Melanoma
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Withdrawn

Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)

Liver Cirrhosis | HIV Infections | Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Hepatitis B, Chronic
National Institute of Allergy and Infectious Diseases...

Terminated

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Hepatitis | HIV/AIDS

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

Head and Neck Cancer

United States
Biolex Therapeutics, Inc.

Completed

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C (PLUS)

Hepatitis C

United States
M.D. Anderson Cancer Center
Novartis

Completed

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myeloid, Chronic

United States
University of Modena and Reggio Emilia
Merck Sharp & Dohme LLC

Unknown

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)

Menopause | Chronic Hepatitis C

Italy
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Suspended

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
California Cancer Consortium
National Cancer Institute (NCI)

Terminated

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
Ochsner Health System
NewLink Genetics Corporation

Unknown

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Melanoma

United States
National Cancer Institute (NCI)

Terminated

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Rennes University Hospital

Completed

Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (BocepreVIH)

HIV-1 Infection | HCV Coinfection

France
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Unknown

Adjuvant PEG Intron in Ulcerated Melanoma

Ulcerated Melanomas

France, Denmark, Italy, Belgium, Spain, United Kingdom, Netherlands, Austria, Germany, Poland, Switzerland, Portugal
M.D. Anderson Cancer Center
Schering-Plough; Eisai Inc.

Terminated

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Melanoma

United States
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC; Novartis; Uppsala University Hospital

Terminated

Nilotinib Plus Pegylated Interferon-α2b in CML

Chronic Myeloid Leukemia

Netherlands, Denmark, Sweden, Finland, Norway
Merck Sharp & Dohme LLC

Completed

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Hepatitis C, Chronic
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Regional Gastrointestinal Carcinoid Tumor

United States
Hoffmann-La Roche

Completed

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Ireland, Taiwan, Estonia, Hungary, Italy, Romania, United Kingdom, Serbia, Morocco, Portugal, Saudi Arabia, Egypt, Pakistan, Lebanon, Macedonia, The Former Yugoslav Republic... and more
Merck Sharp & Dohme LLC

Completed

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

Neoplasms
Arbeitsgemeinschaft medikamentoese Tumortherapie
AOP Orphan Pharmaceuticals AG

Completed

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Chronic Phase Chronic Myeloid Leukemia

Austria
Beth Israel Deaconess Medical Center
Schering-Plough

Completed

Study of Long-term Peg Intron vs. Colchicine in Non-responders. (COPILOT)

Cirrhosis | Hepatitis C Virus | Advanced Fibrosis

United States
Merck Sharp & Dohme LLC

Completed

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Melanoma
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Hepatitis C, Chronic
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Essential Thrombocytopenia

China
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Hepatitis C

Japan
Emory University
Bayer

Completed

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Carcinoma, Squamous Cell | Squamous Cell Carcinoma of Skin

United States
Columbia University
Merck Sharp & Dohme LLC

Withdrawn

Boceprevir in End Stage Renal Disease (ESRD)

End Stage Renal Disease | Hepatitis C Infection
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

HIV Infections | Hepatitis C

United States, Puerto Rico
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Essential Thrombocytopenia

China
Chronic Liver Disease Foundation
Merck Sharp & Dohme LLC; SCRI Development Innovations, LLC

Completed

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy (OPTIMAL)

Chronic Hepatitis C | Genotype 1

United States

Search clinical trials for: PEG Interferon Alfa-2b

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations